Molecular Partners AGMLLCF 25 Current Ratio is 9.42 as of Mar. 2026, which is 9% below its 10-year median of 10.34. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.51 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,417 Biotechnology companies, Molecular Partners AG ranks better than 76.15% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Molecular Partners AG's current ratio for the quarter that ended in Mar. 2026 was 9.42.
Molecular Partners AG has a current ratio of 9.42. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Molecular Partners AG's Current Ratio or its related term are showing as below:
MLLCF'
s Current Ratio Range Over the Past 10 Years
Min: 2.32 Med: 10.34 Max: 18.92
Current: 9.42
During the past 13 years, Molecular Partners AG's highest Current Ratio was 18.92. The lowest was 2.32. And the median was 10.34.
MLLCF's Current Ratio is ranked better than 76.15% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs MLLCF: 9.42
Molecular Partners AG (OTCPK:MLLCF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Molecular Partners AG Current Ratio Related Terms
Molecular Partners AG Current Ratio Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLLCF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Molecular Partners AG's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Current Ratio distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG (MLLCF) has a Current Ratio of 9.42 as of Mar. 2026. This is near median its historical median of 10.34. Over the past decade, Molecular Partners AG's Current Ratio has ranged from 2.32 to 18.92. According to the industry distribution chart, Molecular Partners AG ranks #338 out of 1417 companies in the Biotechnology industry, placing it in the top 23.9%.
Is Molecular Partners AG's Current Ratio too high?
Molecular Partners AG's current Current Ratio of 9.42 is near median its 10-year median of 10.34. Over the past 10 years, this metric has ranged from a low of 2.32 to a high of 18.92. The Biotechnology industry median Current Ratio is 3.89. Molecular Partners AG's value of 9.42 is 142.2% above this industry median. Based on the distribution chart, Molecular Partners AG ranks #338 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #338 out of 1417 companies for Current Ratio. This places Molecular Partners AG in the top 24% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Molecular Partners AG's value of 9.42 is 142.2% above this benchmark. Historically, Molecular Partners AG's own Current Ratio has ranged from 2.32 to 18.92 over the past decade. While the company's 10-year median is 10.34 vs. the industry median of 3.89, Molecular Partners AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Molecular Partners AG's current Current Ratio of 9.42 is 142.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current Current Ratio is 9.42, which is near median its own 10-year median of 10.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.51, compared to a current price of $3.60 — trading 605.9% above its estimated fair value. The current Current Ratio is 9.42, which is near median its 10-year median of 10.34 and 142.2% above the Biotechnology industry median of 3.89. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Current Ratio is 9.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (MLLCF) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of $3.60 is trading 605.9% above its estimated GF Value™ of $0.51.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for MLLCF:
Current Ratio: 9.42 (near median its 10-year median of 10.34)
GF Value™: $0.51 vs. price of $3.60 (605.9% above fair value)
Industry Position: 142.2% above the Biotechnology median (#338 of 1417)
No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score
Get the complete analysis for MLLCF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
